ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical's DynamX Bioadaptor ...
Elixir Medical's INFINITY-SWEDEHEART trial of DynamX Bioadaptor meets primary endpoint of target lesion failure (TLF) non-inferiority at 12 months, with low event rates despite complex patient population. Landmark analysis shows significant reduction in TLF and target vessel failure (TVF) after six months, confirming the unique mechanism of action.
Reference News
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical's DynamX Bioadaptor ...
Elixir Medical's INFINITY-SWEDEHEART trial of DynamX Bioadaptor meets primary endpoint of target lesion failure (TLF) non-inferiority at 12 months, with low event rates despite complex patient population. Landmark analysis shows significant reduction in TLF and target vessel failure (TVF) after six months, confirming the unique mechanism of action.